Elizabeth Cairns
Senior Writer
![](/-/media/staff-photos/elizabeth-cairns-round.png?rev=ad88cddf1e62456ba1a87fa30023f281)
Latest From Elizabeth Cairns
Examining The Antibody-Drug Conjugate Pipeline
An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs. The earlier stage pipeline boasts a range of mechanistic approaches.
Boehringer Looks To Revitalise Its Pipeline
With sales of its big sellers Jardiance and Ofev to start shrinking in the next few years, the German group is teeing up a suite of new drugs.
Roche Could Have The Best Obesity Pill
That is, if very early data in a handful of patients are borne out in later, larger studies.
The IPO Queue Fills Up, But A Recovery Is A Way Off
Six biopharma companies have filed to list their shares on US exchanges so far this year, but the sums they are seeking are small.
CNS Drugs Are Surprisingly Valuable
An analysis of the most valuable research-stage products pinpoints several neurological candidates – and a deeper dive into this segment shows more CNS therapies that look to be worth big money.
The Prospects For Earlier-Stage Antibody-Drug Conjugates
Around 25 ADCs are in active Phase I/II trials, with a range of mechanistic approaches.